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Abstract
Dietary management of the human gut microbiota towards a more beneficial composition is
one approach that may improve host health. To date, a large number of human intervention
studies have demonstrated that dietary consumption of certain food products can result in
significant changes in the composition of the gut microbiota i.e. the prebiotic concept. Thus
the prebiotic effect is now established as a dietary approach to increase beneficial gut bac-
teria and it has been associated with modulation of health biomarkers and modulation of the
immune system. Promitor™ Soluble Corn Fibre (SCF) is a well-known maize-derived
source of dietary fibre with potential selective fermentation properties. Our aim was to deter-
mine the optimum prebiotic dose of tolerance, desired changes to microbiota and fermenta-
tion of SCF in healthy adult subjects. A double-blind, randomised, parallel study was
completed where volunteers (n = 8/treatment group) consumed 8, 14 or 21 g from SCF (6,
12 and 18 g/fibre delivered respectively) over 14-d. Over the range of doses studied, SCF
was well tolerated Numbers of bifidobacteria were significantly higher for the 6 g/fibre/day
compared to 12g and 18g/fibre delivered/day (mean 9.25 and 9.73 Log10 cells/g fresh fae-
ces in the pre-treatment and treatment periods respectively). Such a numerical change of
0.5 Log10 bifidobacteria/g fresh faeces is consistent with those changes observed for inu-
lin-type fructans, which are recognised prebiotics. A possible prebiotic effect of SCF was
therefore demonstrated by its stimulation of bifidobacteria numbers in the overall gut micro-
biota during a short-term intervention.
Introduction
The colon contains the most abundant and diverse assemblage of bacteria in the human body
[1]. Symbiotic interactions within this complex community are now recognized as important
mediators of health by the scientific community [2]. Like other environmental microbial com-
munities, the human microbiome is a complex and dynamic system that plays an important
role in many aspects of host physiology [3–6]. Together with the gut immune system, colonic
and mucosal microbiota contributes to a barrier that prevents pathogenic bacteria from
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invading the gastrointestinal (GI) tract. Generally, bacteria that have an almost exclusive sac-
charolytic metabolism can be generally considered as beneficial, e.g. bifidobacteria [7–11]. The
intestinal microbiota salvages energy through fermentation of carbohydrates and other sub-
strates not digested in the upper gut [12–14]. In addition, some dietary protein may reach the
colon, while endogenous secretions, including mucin, provide diet-independent substrates.
Many secondary plant metabolites ingested with the diet, such as polyphenolic substances,
may also reach the large intestine and are subject to bacterial transformation. [14]. Colonic bac-
teria use a range of carbohydrate hydrolyzing enzymes to produce gases and organic acids. Die-
tary components that stimulate fermentation lead to an increase in bacterial mass and
consequently faecal mass and, thus have a stool bulking effect [15]. It is estimated that about 30
g of bacteria are produced for every 100 g of carbohydrate that is fermented. According to Gib-
son and Roberfroid [16] predominant bacterial groups of the human gut microbiota may be
classified into those that are either beneficial with health promoting effects; harmful or patho-
genic; or those that demonstrate both or no effects.
Members of nine bacterial phyla were found to inhabit the human gastrointestinal tract, of
which Firmicutes and Bacteroidetes are the dominant ones, while Actinobacteria and Proteoba-
teria subdominants [4]. Besides the low level of biodiversity at the phylum level, the human
intestinal microbiota is tremendously diverse at species and subspecies level [3]. It is character-
ized by a considerable interpersonal variation in bacterial species and strains [7] and, up to
now, 1000 different bacterial species-level phylogenetic types have been identified in the
human intestinal microbiota. However, because of a significant degree of functional redun-
dancy, the differences in the microorganism lineage between individuals are greater than differ-
ences in the representation of the gene networks embedded in the individual microbiomes. To
date, it seems clear that the relative composition of microbes within the gut microbiota is
largely reliant upon food consumed, one opportunity for modulate the microbiome is through
dietary change [17–20]. For this reason, dietary management of the human gut microbiota
towards a more beneficial composition is an approach that can improve host health [21–22].
Bacteria such as bifidobacteria and lactobacilli have demonstrable beneficial effects through
improving resistance to gut infections by inhibiting the growth of harmful bacteria [23], pro-
tecting against bacterial invasion [24], reducing cholesterol levels [25–26], improving the
immune response [27] and producing vitamins within the gut [28].
The scientific understanding of dietary modulation of the human gut microbiota has been
developed over several decades, with probiotics as a principal focus [18, 22]. While the role of
probiotics has been widely advocated, it is possible that a greater number of food products will
further exploit the prebiotic approach over the next few years. Prebiotics can also be added to
many foods including those which are cooked or baked, which are more problematic for probi-
otic enrichment [29–30].
A maize-based soluble fibre, Soluble Corn Fibre (SCF), has been shown to be a versatile
source of dietary fibre with potential selective fermentation properties as determined in vitro
[31] and in vivo [32]. SCF is a glucose polymer obtained from a partially hydrolyzed starch-
made glucose syrup. Possessing a high digestive tolerance after ingestion [33–35], SCF has also
been shown to elicit a low post-prandial blood glucose and insulin response (i.e. reduced glyce-
mic potential) [33]. Recently, SCF has been shown to improve bone properties [36], ameliorate
the immune response in experimental colitis [35], and improve laxation [37–38], which is one
of the most well noted benefits of dietary fibres. Key to the establishment of novel prebiotic
products is assessment of an optimum dose level required to elicit changes in the gut micro-
biota during feeding. Therefore, the aim of the present pilot human study was to determine the
effect of different doses of SCF for prebiotic potential in healthy volunteers and their impact on
the human intestinal microbial ecosystem. Stool samples were collected before and after
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treatment and changes within the gut microbiota profile were determined. Nine 16S rRNA-
based fluorescence in situ hybridization probes were used to target predominant groups/species
of human faecal microbiota. Gastrointestinal symptoms and stool characteristics such as stool
frequency, consistency, abdominal pain, intestinal bloating and flatulence were also recorded
in order to assess prebiotic tolerance.
Materials and Methods
Selection and characteristics of study population
Twenty-four healthy volunteers (gender: 12 female, 12 male; age: mean 33, range 18 to 50 yr;
body mass index (BMI): mean 23.6 kg/m2, range 20.1 to 29.7 kg/m2) were recruited from the
local community. The study was approved by the University of Reading Research Ethics Com-
mittee prior to the start of the study and written informed consent was obtained from all sub-
jects prior to commencement of selection. Inclusion criteria were males and females from 18 to
50 years of age and BMI 18.5 to<30 kg/m2. General health status was assessed using a pre-
study medical questionnaire and putative volunteers were excluded if they fulfilled any of the
following exclusion criterion: diagnosed as suffering from any chronic gastrointestinal com-
plaints (including chronic constipation, diarrhoea or irritable bowel syndrome), diabetes or
anaemia; requirement to take long-term medication active on the gastro-intestinal tract, for the
treatment of cardio-vascular disease, or any other long-term medication; high blood choles-
terol or use of cholesterol lowering drugs/functional foods; history of drug or alcohol misuse or
alcohol consumption exceeding 14 and 21 units/week for females and males respectively; those
suffering with any allergies to medication or food; smokers, and those on weight reducing
diets. Females were excluded who were either planning pregnancy within six months of the
start of the study, lactating, or had given birth within the preceding six months. Specified timed
exclusion criteria included use of antibiotics with the previous six months, participation in any
probiotic, prebiotic or laxative study in the previous three months, or intake of an experimental
drug within four weeks of the study start. Consumption of any probiotic or prebiotic products
and use of medication active on the gastrointestinal tract or use for the treatment of abdominal
pain, intestinal discomfort, or constipation were prohibited during the four weeks prior to
commencement of the study and for the duration of the study.
Study design and treatments
The overall study design is outlined in Fig 1 and was completed in a double-blind manner, with
two experimental periods (pre-treatment and treatment period) each lasting 14 days. Eight vol-
unteers were randomly allocated on the basis of age and BMI to each of three treatment groups.
The treatments were designed to provide a total of 8, 14 or 21 g from SCF (Promitor™ Soluble
Corn Fibre, SCF) (equivalent to 6, 12 and 18 g/fibre delivered, respectively). Supplements were
provided by Tate & Lyle, France, as dry powders and were consumed as 250 ml beverages twice
daily. Volunteers were requested to substitute 500 ml of their normal daily fluid intake to com-
pensate for the volume of water consumed with the treatments. Freshly voided faecal samples
were provided by each volunteer at the end of the pre-treatment period (baseline sample) and
then after 14 days of dietary intervention during the treatment period.
Faecal samples were collected in sterile plastic containers, stored in an anaerobic cabinet
(10% H2; 10% CO2; 80% N2) and then processed within two hours of collection.
Throughout the pre-treatment and treatment periods, volunteers recorded details of bowel
habits including stool frequency and consistency (Bristol stool scale) [39], stomach or intestinal
bloating, abdominal pain, incidence and frequency of flatulence and stomach noises. This
Prebiotic Potential Impact of Maize-Based Soluble Fibre
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information was recorded as being indicative of digestive tolerance. In addition, volunteers
recorded details of dietary intake on four days within each period (data not reported).
Faecal preparation and enumeration of faecal microbial populations by
fluorescence in situ hybridisation
Freshly voided faecal samples (~ 2–5 g) were diluted 1 in 10 (w/w) with sterile, anaerobic phos-
osphate buffered saline (PBS, 0.1M; pH 7.0) and homogenised using a Stomacher 4001 (Sew-
ard, Norfolk, UK) for 2 min at normal speed.
Fluorescence in situ hybridisation (FISH) was performed as described by Costabile et al.
[40]. The composition of hybridisation and wash buffers depends on the rRNA-targeted oligo-
nucleotide probe as reported in probeBase (http://www.microbial-ecoLogy.net/probebase) and
was used accordingly. All oligonucleotide probes used in the study are reported in Table 1 [40].
Briefly, aliquots (375 μl) of 1 in 10 w/w stool sample suspension in PBS, 0.1M were fixed over-
night at 4°C with 4% (w/v) filtered paraformaldehyde (pH 7.2) in a ratio of 1:4 (v/v), washed
twice with filtered PBS (0.2 μm pore size), resuspended in 300 ml of a PBS/ethanol mixture
(1:1, v/v) and then stored at– 20°C for up to 3 months. For the hybridizations, 20 μl of each
sample was pipetted onto Teflon and poly-L-lysine-coated, six-well (10 mm diameter each)
slides (Tekdon Inc., Myakka City, FL). To permeabilize the cells for use with probe Lab158,
samples were treated with 50 μl of lysozyme (1 mg/ml in 100 mM Tris-HCl, pH 8.0) at 37°C
for 15 min before being washed (2–3 s) in water and were finally dehydrated in the ethanol
series (50%, 80% and 96% v/v ethanol, 3 min each). A probe/hybridization buffer mixture
(5 ng/5 μl of a 50 ng/μl probe in stock solution plus 45 μl of hybridization buffer) was applied
Fig 1. Study design of a double-blind, randomised, parallel study with eight volunteers per treatment
group, and consisting of a pre-treatment and treatment period (14-days). Treatments with were 8, 14
and 21 g-SCF/d designed to 6, 12 and 18 g fibre/delivered/day from Promitor™ Soluble Corn Fibre (SCF).
doi:10.1371/journal.pone.0144457.g001
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onto the surface of each well. Hybridizations were performed for 4 h in an ISO20 oven (Grant
Boekel). For the washing step, slides were placed in 50 ml of wash buffer containing 20 μl of 4,
6-diamidino-2-phenylindole di-hydrochloride (DAPI; 50 ng/μl; Sigma, UK) for 15 min. They
were then washed (2–3 s) in ice-cold water and dried under a stream of compressed air. Five μl of
antifade reagent (polyvinyl alcohol mounting medium with DABCOTM antifading, Sigma) was
added to each well and a coverslip was applied. Slides were stored in the dark at 4°C (for a maxi-
mum of 3 days) until cells were counted under a Nikon E400 Eclipse microscope. DAPI slides
were visualized with the aid of a DM 400 filter and probe slides with the aid of a DM 575 filter.
The probes were commercially synthesized and labelled at the 5’ end with the fluorescent
dye Cy3 (Sigma-Aldrich, Poole, Dorset, UK).
Faecal moisture content
Faecal moisture content was determined following oven drying a representative sub-sample of
each faecal sample in a fan-assisted oven at 100°C for 18 h.
Data transformations and statistical analysis
Data for the enumeration of the key beneficial groups of faecal bacteria were expressed as
Log10 cells/g fresh faeces. Within each treatment group the results for digestive tolerance and
Table 1. Probes used for Fluorescence in situ hybridization (FISH) analysis of bacterial populations in human faeces.
Short
name
Accession
no.*
Full name Target species Sequence (5´ to 3´)
Bif164 pB-00037 S-G-Bif-
0164-a-A-18
Most Biﬁdobacterium spp. and Parascardovia denticolens CATCCGGCATTACCACCC
Lab158 ND S-G-Lab-
0158-a-A-20
Most Lactobacillus, Leuconostoc andWeissella spp.;
Lactococcus lactis; all Vagococcus, Enterococcus,
Melisococcus, Tetragenococcus, Catellicoccus, Pediococcus
and Paralactobacillus spp.
GGTATTAGCAYCTGTTTCCA
Bac303 pB-00031 S-*-Bacto-
0303-a-A-17
Most Bacteroides sensu stricto and Prevotella spp.; all
Parabacteroides; Barnesiella viscericola and Odoribacter
splanchnicus
CCAATGTGGGGGACCTT
Chis150 pB-00962 S-*-Chis-
0150-a-A-23
Most members of Clostridium cluster I; all members of
Clostridium cluster II; Clostridium tyrobutyricum; Adhaeribacter
aquaticus and Flexibacter canadensis (family
Flexibacteriaceae); [Eubacterium] combesii (family
Propionibacteriaceae)
TTATGCGGTATTAATCTYCCTTT
Ato291 pB-00943 S-*-Ato-
0291-a-A-17
Atopobium, Colinsella, Olsenella and Eggerthella spp.;
Cryptobacterium curtum; Mycoplasma equigenitalium and
Mycoplasma elephantis
GGTCGGTCTCTCAACCC
Erec482 pB-00963 S-*-Erec-
0482-a-A-19
Most members of Clostridium cluster XIVa; Syntrophococcus
sucromutans, [Bacteroides] galacturonicus and [Bacteroides]
xylanolyticus, Lachnospira pectinschiza and Clostridium
saccharolyticum
GCTTCTTAGTCARGTACCG
Eub I-II-III pB-00159-
160-161
S-D-Bact-
0338-a-A-18
Most domain bacteria GCT GCC TCC CGT AGG AGT
Rrec584 ND ND Roseburia genus TCAGACTTGCCG(C/T)ACCGC
EC1531 ND L-S-Eco-
1531-a-A-21
Escherichia coli CACCGTAGTGCCTCGTCATC
*ND, No information relating to these probes has been deposited in probeBase (http://www.microbial-ecology.net/probebase).
‡These probes were used together in equimolar concentrations (both at 50 ng μl−1).
Formamide (20%) was included in the hybridization buffer.
doi:10.1371/journal.pone.0144457.t001
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faecal bacteriology were analysed using paired t-tests (i.e. pre-treatment vs. treatment values)
within the Minitab1 Software (Windows V15). Significance was set at P<0.05.
Results
Bowel habit and indicative digestive tolerance
A summary of the mean bowel habit and indicative digestive tolerance recorded within each
treatment group (i.e. 8 volunteers/treatment group) in both the 14-day pre-treatment and
treatment periods is shown in Table 2. With the exception of bowel movement recordings
(number/day) and stool consistency (score 1 to 7 representing hard to entirely liquid stools),
volunteer responses were ranked to give rise to scores, whereby 0 indicated no symptoms,
1 indicated very mild symptoms and 10 indicated very severe symptoms. The data show that
there was no significant effect (P>0.05) of treatment on the mean number of bowel movements
per day (1.34, 1.53, and 1.47 no/day, across respective treatments) or on stool consistency (3.7,
3.8, and 4.1, across respective treatments), values of which were similar across all treatment
groups (overall mean across all treatment groups in the pre-treatment and treatment periods
respectively). Determination of stool dry weight also showed that there was no significant effect
(P>0.05) of treatment on this between treatment groups (23.7, 28.3, and 27.1 g/100g, respec-
tively) and that values were similar across all treatments (overall mean across all treatments
26.3, 25.6 and 26.2 g/100g fresh stool in the pre-treatment and treatment periods respectively).
There was a significant effect on flatulence with the 14 g-SCF treatment, 1.33 and 2.28 in the
pre-treatment and treatment periods). However, the effect of the treatment on flatulence was
small, with overall values reported as none to very mild in the 14g-SCF treatment, and further-
more was not statistically significant in the 21g-SCF treatment. There was no significant effect
of treatment on bloating, abdominal pain or stomach occurrences in any treatment group.
Enumeration of faecal microbial populations
Effects of the three treatments studied on predominant groups of the human gut microbiota
are summarised in Table 3 and expressed as Log10 cells/g fresh faeces. FISH analysis showed
Table 2. Summary of the mean stool frequency and consistency, and indicative digestive tolerance recorded daily by eight volunteers per treat-
ment group for each of 14 days in the pre-treatment (baseline) and treatment periods. Values in parenthesis are standard error (SE) values.
8 g-SCF (6g/ﬁbre/delivered/d) 14 g-SCF (12g/ﬁbre/delivered/d) 21 g-SCF
(18g/ﬁbre/delivered/d)
Parameter Pre-treatment Treatment Pre-treatment Treatment Pre-treatment Treatment
Bowel movements (no./day) 1.34 (0.13) 1.34 (0.14) 1.43 (0.16) 1.53 (0.15) 1.35 (0.21) 1.47 (0.16)
Stool consistency1 3.6 (0.20) 3.7 (0.20) 3.7 (0.26) 3.8 (0.15) 3.8 (0.22) 4.1 (0.22)
Bloating2 0.51 (0.27) 0.89 (0.60) 0.12 (0.11) 0.42 (0.17) 1.15 (0.52) 0.93 (0.31)
Abdominal pain2 0.77 (0.46) 0.61 (0.46) 0.05 (0.04) 0.23 (0.16) 0.98 (0.47) 0.71 (0.28)
Flatulence2 1.54 (0.41) 1.84 (0.66) 1.33 (0.36) 2.28 (0.38)** 1.46 (0.31) 2.50 (0.78)
Stomach noises2 0.73 (0.25) 0.92 (0.45) 0.40 (0.15) 0.96 (0.37) 0.49 (0.20) 1.30 (0.67)
Stool dry weight (g/100 g)3 26.3 (2.71) 23.7 (1.98) 25.6 (3.37) 28.3 (2.08) 26.2 (2.00) 27.1 (1.63)
Promitor™ Soluble Corn Fibre (SCF) 8, 14 and 21 g-SCF, treatments designed to provide 6, 12 and 18 g ﬁbre/delivered/day from SCF.
1, estimated using the Bristol stool chart (scale with seven stool types; Type 1 –hard to Type 7 –entirely liquid).
2, overall scale from 0 to 10 (0—no symptoms; 1 –very mild symptoms to 10 –very severe symptoms).
3,stool dry weight determined following oven drying at 100°C for 18 h.
*, P<0.05.
**, P<0.01 (vs pre-treatment).
doi:10.1371/journal.pone.0144457.t002
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that there was a significant increase (P<0.05) in concentration of health-promoting genus Bifi-
dobacterium (Bif164) following consumption of the 6 g fibre/delivered/day when compared to
the pre-treatment period. However, there was no significant increase (P>0.05) in numbers of
bifidobacteria for any of the other treatment groups, although the 18 g/ fibre/delivered/day
indicated a trend (P = 0.083) for an increase (mean 9.41 and 9.65 Log10 cells/g fresh faeces
in the pre-treatment and treatment periods respectively). There was no significant effect
(P>0.05) on lactobacilli although there was a trend (P = 0.09) for values to increase following
14-d consumption of the 6 g/ fibre/delivered/day (mean 8.07 and 8.37 Log10 cells/g fresh faeces
in the pre-treatment and treatment periods respectively). A significant decrease (P<0.05) in
numbers of C. histolyticum /perfringens group following consumption of the 12 g/ fibre/deliv-
ered/day was observed (mean 7.72 and 7.19 Log10 cells/g fresh faeces in the pre-treatment and
treatment periods respectively. Eubacterium rectale-Clostridium coccoides group enumerated
by the Erec482 probe did not significantly influence (P> 0.05) their concentrations. A similar
behaviour was demonstrated for Bacteroides-Prevotella group (detected by Bac303), Rrec584
probe enumerating the butyrate-producing E. rectale-Roseburia group, also a component of
cluster XIVa, the Atopobium group (detected by Ato291) comprises bacteria of the Coriobacter-
iaceae family, belonging to Coriobacterium, Atopobium and Collinsella genera and E. coli
(detected by Ecoli1351), whose concentrations were stably maintained during the study.
Discussion
Bowel habits and indicative digestive tolerance
The results of this ‘pilot’ study has demonstrated that SCF was well tolerated at daily dose levels
of 6, 12 and 18 g/fibre/delivered/d following 14-day dietary interventions in healthy adults.
Overall volunteer responses for stomach/intestinal bloating, abdominal pain, flatulence and
stomach noises were recorded as none to mild (i.e. overall score<4). These results are in agree-
ment with previous studies [32, 33, 41, 42, 43, 44] on the digestive tolerance of prebiotics,
including those determined in a single amount up to 65 g fibre/d [45]. The authors also
Table 3. Enumeration of faecal microbial populations in fresh stool samples collected from eight volunteers per treatment group both before (pre-
treatment/baseline) and following 14-day dietary intervention (treatment) in a double-blind, randomised, parallel study. Stool bacterial numbers as
determined by fluorescence in situ hybridisation are expressed as mean Log10 cells/g fresh faeces (values in parenthesis are standard error (SE) values).
Bacterial group Probe 8 g-SCF 14 g-SCF 21 g-SCF
Pre-
treatment
Treatment† Pre-
treatment
Treatment Pre-
treatment
Treatment
Total bacteria Eub338
I-II-III
11.0 (0.07) 11.0 (0.09) 11.1 (0.08) 11.1 (0.12) 11.1 (0.10) 11.2 (0.06)
Bacteroides/Provotella gp. Bac303 10.1 (0.05) 10.2 (0.07) 10.4 (0.11) 10.2 (0.06) 10.3 (0.07) 10.4 (0.08)
Lactobacilli/enterococci Lab158 8.07 (0.20) 8.37 (0.17) 7.87 (0.23) 7.71 (0.33) 8.08 (0.12) 8.07 (0.20)
Biﬁdobacterium spp. Bif164 9.25 (0.27) 9.73 (0.22)* 9.26 (0.26) 9.35 (0.43) 9.41 (0.11) 9.65 (0.09)
Coriobacteriaceae Ato291 9.43 (0.10) 9.37 (0.08) 9.47 (0.16) 9.39 (0.17) 9.46 (0.12) 9.52 (0.08)
C. histolyticum /perfringens gp. Chis150 7.34 (0.15) 7.22 (0.14) 7.72 (0.16) 7.19 (0.22)
*
7.51 (0.33) 7.59 (0.31)
Clostridium coccoides-Eubacterium rectale
gp.
Erec482 10.3 (0.09) 10.3 (0.08) 10.4 (0.06) 10.4 (0.07) 10.4 (0.07) 10.3 (0.08)
Eubacterium rectale-Roseburia sub-gp. Rrec584 9.87 (0.19) 9.97 (0.11) 10.0 (0.08) 9.95 (0.12) 10.0 (0.08) 9.94 (0.10)
Escherichia coli Ecoli1351 8.05 (0.28) 8.00 (0.23) 7.68 (0.16) 7.68 (0.20) 10.0 (0.08) 9.94 (0.10)
†Treatments with 8, 14 and 21 g-SCF designed to provide 6, 12 and 18 g ﬁbre/delivered/day from Promitor™ Soluble Corn Fibre (SCF).
*, P<0.05 (vs pre-treatment).
doi:10.1371/journal.pone.0144457.t003
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concluded that SCF was well tolerated at daily amounts as high as 65g [45], whereas some can-
didate prebiotic fibres have been shown to induce a mild laxation effect, increasing stool fre-
quency and weight when consumed at high doses (>20 g/day)
In addition to the high digestive tolerance afforded by SCF, the present study showed that
treatments were well tolerated as seen by no significant adverse effect on bowel habits, as deter-
mined by stool frequency and consistency, with similar values recorded both before and follow-
ing 14-days of intervention. The values of 1.41 and 1.46 bowel movements per day recorded
across all treatments in the pre-treatment and treatment periods are within the range previ-
ously reported [12–13]. For adults across Western countries, these authors state that the modal
stool frequency is 1 per day; for the population as a whole the range is 3 stools per day to 3
stools per week [12–13]. Stool consistency was unchanged by dietary intervention and it is
interesting to note that there was close agreement in the findings of the subjective assessment
of stool consistency using the Bristol stool chart (recorded daily across 14 days during the pre-
treatment and treatment periods) and objective assessment of stool moisture content (i.e. oven
drying at 100°C for 18 h). Determination of stool consistency is an important attribute in the
overall assessment of digestive tolerance and is related to stool moisture content (normal
range, 70–80 g moisture/100 g fresh stool [13]). Therefore, the present study validates the
approach of recording a subjective assessment of stool consistency in bowel habit diaries for
use in dietary intervention studies since it is impracticable to routinely oven dry stool samples.
Assessment of prebiotic potential
Prebiotics are defined as ‘non digestible food ingredients that are selectively metabolised by
colonic bacteria that have the capacity to improve health’ [16,17]. Prebiotics, in part due to
their function as a special type of soluble fibre, can contribute to the health of the general popu-
lation; and a number of challenges must be addressed in order to fully realize prebiotic benefits,
including the need for greater awareness of the accumulated evidence on prebiotics among pol-
icy makers [22]. According to Tuohy et al. [42], the most frequently tested prebiotics are the
non-digestible oligosaccharides, such as the fructans and galactans, which confer selective
increases in bifidobacteria following short feeding periods.
While many non-digestible ‘by-pass’ carbohydrate materials/products may be potential can-
didate prebiotics, this classification cannot be extended to all non-digestible carbohydrates and
dietary fibres [16]. Key to the establishment of novel prebiotic products is assessment of an
optimum dose level required to elicit changes away from a gut flora dominated by potentially
harmful bacteria towards a more benign, or beneficial, composition, since there is currently no
recommended daily intake of prebiotics [16]. The current study examined the effect of 3 doses
of SCF (6g, 12g and 18 g fibre/delivered/day from SCF) on the human gut microbiota following
a 14-d intervention. In the present study, fluorescence in situ hybridization (FISH) method
instead of 16S sequencing was used to better focus on some key taxa of interest and to obtain
numerical counts of bacterial groups that are considered relevant based on previous work. Fur-
thermore, 16S sequencing approaches might lead to bias and has previously led to under-repre-
sentation of bifidobacteria. Numbers of bifidobacteria were shown to be significantly higher for
the 8 g-SCF treatment. The numerical increase of 0.5 Log10 bifidobacteria/g fresh stool is con-
sistent with numerical changes of 0.5–1.0 Log10 observed for inulin-type fructans [33] which
are thought to exert their prebiotic effects at doses higher than 5 g/d–usually 8 g/d. According
to Kolida and Gibson [46] such a change in numbers of bifidobacteria ‘constitutes a major shift
in the gut microbiota towards a “healthier” composition’. This prebiotic effect concurs with
that demonstrated in vitro, whereby relative numbers of bifidobacteria were shown to increase
[46]. In addition, results of in vivo and in vitro studies show that SCF promotes the production
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of SCFA including butyrate, which are positively associated with colonic health. However,
increasing levels of SCFA was generally not associated with further significant changes in num-
bers of bifidobacteria [47].
This is concordant with other in vivo intervention studies with fructans which often
reported increases between 0.5–1.0 Log10 bifidobacteria counts [46]. However, the magnitude
of increase seems to depend on the baseline values and higher increases are often observed in
volunteers with low initial bifidobacteria numbers. While the bifidogenic potential is well-
proven the effect of consumption of SCF on other bacteria groups is less well established. A
decrease in clostridia was mainly reported at the dose of 12 g/fibre/delivered/day compared to
the pre-treatment. However, it cannot be determined whether the decrease in clostridia after
SCF intake should be seen as detrimental.
The present study has demonstrated that the optimum prebiotic dose-response was 6 g
fibre/delivered/day from SCF. A low dose of SCF was shown to stimulate bifidobacteria in the
gut microbiota. However, such an increase in numbers of bifidobacteria has been demonstrated
over a wide range of doses in previous prebiotic studies [47–48]. The range in dose levels has
been estimated to be 3–20 g/d [33] and 4–40 g/d [34] for inulin, although for individual prebio-
tics, differences in optimal dose level are likely to vary according to several factors including,
degree of polymerisation and molecular weight [42]. An increase in the dose of SCF greater
than 6 g fibre/delivered/day was generally not associated with further stimulation of the bacte-
rial groups included for study here. This absence of a quantifiable or defined effect with
increasing prebiotic inclusion is in general agreement with previously published studies investi-
gating prebiotic dose-response effects [49–51]. In a placebo-controlled, cross-over study
(n = 30), Kolida et al. [46] showed that there was no dose-response relationship following
ingestion of 8 g inulin/d. Comparing daily doses of 5, 10, 20 and 40 g gum Arabic/d [52] the
authors showed that the optimum daily dose was approximately 10 g/d. The explanation for
the general absence of dose-response relationships is not widely understood. One such expla-
nation proposed by Calame et al. [52] is at high doses other bacterial strains have easier access
to the substrate and subsequently, less becomes available for the ones determined within their
study. This is a possibility requiring further research.
In the current study numbers of faecal lactobacilli/enterococci were unchanged compared to
pre-treatment values although a mean numerical increase of 0.3 Log10 cells/g fresh stool was
recorded for the 6 g/fibre/delivered/day as compared to the pre-treatment. Since no significant
effect of dietary intervention was observed on numbers of total bacteria results of the present study
suggest that consumption of 6 g/ fibre/delivered/day from SCF is selectively fermented by Bifidobac-
terium spp. and that their relative contribution to the overall gut microbiota is thereby increased.
In conclusion, SCF is a fibre source, which was well tolerated in doses as high as 18 g/ fibre/
delivered/day in this study. A possible prebiotic effect was demonstrated by its stimulation of
numbers of bifidobacteria in the overall gut microbiota following consumption of 6 g fibre/
delivered/day. Further work is required to demonstrate the effect of SCF on other bacterial
populations and in a placebo-controlled, cross over study–to assess specificity and therefore to
support the potential application of this novel fiber as prebiotic in human nutrition.
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